Health News Releases

April 15, 2019 09:45

New post-hoc analysis of EMPA-REG OUTCOME® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced results from a new cost-effectiveness analysis of the EMPA-REG OUTCOME® trial in a subgroup of 2,250 people with type 2 diabet

April 12, 2019 10:40

ResMed Introduces AirFit P30i, Its First Top-of-Head-Connected Nasal Pillows CPAP Mask

ResMed (NYSE: RMD, ASX: RMD) today introduced its second top-of-head-connected CPAP mask for treating sleep apnea, a new nasal pillows option, AirFit P30i. The mask’s “tube-up” connection, also fea

April 10, 2019 14:10

22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today

April 10, 2019 11:15

Alcon Debuts as Independent, Publicly Traded Company

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced its debut as an independent, publicly traded company and the completion of its separation from Novarti

April 09, 2019 17:25

Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine

Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’. Equine lameness is truly

April 05, 2019 10:40

Graminex L.L.C. Receives NNHPD Health Canada Approval for PollenBerry®

Graminex® L.L.C., producer of Graminex® Non-Solvent Flower Pollen Extracts™, receives Health Canada Approval under the Natural and Non-prescription Health Products Directorate (NNHPD) for its PollenBe

April 02, 2019 13:10

Terns Pharmaceuticals to Present Preclinical Data on Two Lead Programs at the European Association for the Study of the Liver (EASL) Annual Meeting 2019

Terns Pharmaceuticals, Inc. today announced presentation of preclinical data on its two lead programs at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the

April 01, 2019 12:00

Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma

Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regime

April 01, 2019 11:40

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD’s innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this

March 28, 2019 18:00

Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced initial results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world evidence study that show that empa

March 27, 2019 13:40

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) this week shared new data revealing the burden of chronic hypoparathyroidism on patients and caregivers, as well as potential long-

March 26, 2019 13:30

The International Society for Quality in Health Care Partners with the Patient Safety Movement Foundation to Achieve Zero Preventable Deaths in Hospitals

The International Society for Quality in Health Care (ISQua) is pleased to announce their support of the Patient Safety Movement Foundation (PSMF) and their mission to eliminate preventable deaths in

March 26, 2019 11:10

ResMed Launches Next-generation ReSupply Solution

ResMed (NYSE: RMD) (ASX: RMD) today launched its automated ResMed ReSupply solution for all U.S. home medical equipment (HME) providers to increase sleep apnea patients’ long-term therapy adherence an

March 26, 2019 10:00

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with rel

March 25, 2019 10:10

Trueman Man Clinic Achieves 10000 Surgery Milestone with Its SWITCH Operation

Trueman Man Clinic Network announced that the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation), has been successfully completed. The Trueman Man Clinic Netwo

March 22, 2019 16:50

ResMed to Host an Investor Meeting on April 4, 2019

ResMed (NYSE: RMD) (ASX: RMD) today announced it will host an investor meeting on Thursday, April 4th to discuss the Company’s recent acquisitions, existing joint ventures and strategy pertaining to r

March 22, 2019 15:40

Imago BioSciences Announces $40 Million Series B Financing Led by Omega Funds

Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced a $40 million Series B financing led by Omega Funds, a leading in

March 21, 2019 17:49

Seodong Medical Launches Globally Recognized Innovative Device for Treating Dry Eye Syndrome

Innovative products of Seodong Medical Co., a leading dry eye syndrome treatment devices developer, are gaining significant popularity in Korea and other countries as they enhance health of eyeballs.

March 20, 2019 17:59

Dr. Yu-mi Jung of Magic Kiss dental clinic has more scientific teeth contouring and gum forming techniques to complete the ‘Smile Line’ and correct ‘Gummy Smile’

‘Smile Line’ is a virtual line made by the upper and lower lips that reveal the front teeth when smiling. With everything about smiles, the author of Smile Design, and Dr. Jung, president of the Magic

March 19, 2019 11:40

SpeeDx Distribution Network Expands to the Middle East

SpeeDx Pty. Ltd. have announced signing new partners Al Zahrawi Medical Supplies LLC for distribution of ResistancePlus® and PlexPCR® tests across UAE, Saudi Arabia, Oman, Bahrain, and Qatar. “Al Z

March 19, 2019 11:05

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibr

March 18, 2019 17:25

Solasia Files New Medical Device Application for episil® in South Korea

Solasia Pharma K.K. (TOKYO:4597, Headquarters:Tokyo, Japan, President & CEO:Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today officially announced that th

March 15, 2019 11:40

Octapharma Group Reports Strong Results for 2018

Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products. I am particularly pleased with the important reg

March 12, 2019 10:40

Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults w

March 11, 2019 11:10

Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective biologic vedolizumab

News by Region

News by Industry